Compagnie Lombard Odier SCmA Makes New Investment in Abbott Laboratories $ABT

Compagnie Lombard Odier SCmA purchased a new position in shares of Abbott Laboratories (NYSE:ABT) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 675,058 shares of the healthcare product maker’s stock, valued at approximately $84,578,000. Abbott Laboratories makes up 0.9% of Compagnie Lombard Odier SCmA’s investment portfolio, making the stock its 25th largest position.

Several other large investors have also made changes to their positions in the company. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its position in Abbott Laboratories by 15.3% in the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 36,127 shares of the healthcare product maker’s stock worth $4,526,000 after acquiring an additional 4,782 shares in the last quarter. Powerhouse Assets LLC bought a new position in shares of Abbott Laboratories during the 4th quarter valued at $225,000. Victory Financial Group LLC acquired a new stake in shares of Abbott Laboratories in the 4th quarter valued at $272,000. Bourgeon Capital Management LLC bought a new stake in Abbott Laboratories in the fourth quarter worth $432,000. Finally, Lodestone Wealth Management LLC acquired a new position in Abbott Laboratories during the fourth quarter worth $144,000. Institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling

In other news, EVP Elizabeth C. Cushman sold 263 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $30,397.54. Following the sale, the executive vice president owned 38,573 shares in the company, valued at approximately $4,458,267.34. This trade represents a 0.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Eric Shroff sold 709 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $81,946.22. Following the transaction, the senior vice president owned 39,164 shares of the company’s stock, valued at approximately $4,526,575.12. The trade was a 1.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 3,055 shares of company stock valued at $353,097 in the last ninety days. Company insiders own 0.46% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on ABT shares. Weiss Ratings cut Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 26th. Leerink Partners lowered their price objective on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating on the stock in a report on Friday, January 30th. Freedom Capital upgraded Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 29th. Raymond James Financial decreased their target price on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Finally, Barclays dropped their price target on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating on the stock in a research report on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $135.68.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott joined a $575M funding round for wearable maker Whoop as a strategic investor, positioning ABT to participate in consumer health/wearables and personalized‑health data opportunities that could broaden diagnostics and subscription revenue pathways. Abbott joins $575M funding round for wearable maker Whoop
• Positive Sentiment: Abbott integrated its Precision Oncology testing portfolio into Flatiron’s OncoEMR, improving workflow for oncology providers and potentially raising test ordering and revenue capture in oncology diagnostics. Abbott integrates Precision Oncology portfolio into Flatiron’s OncoEMR
• Positive Sentiment: Analyst optimism: Seeking Alpha noted a rating upgrade into Q1 earnings, suggesting some analysts see improving fundamentals and an attractive entry point after recent weakness. Upgrades can help limit downside and attract value buyers. Abbott: A Brighter Investment Case Heading Into Q1 Earnings (Rating Upgrade)
• Neutral Sentiment: Analyst commentaries and comparisons (GEHC vs ABT and sector roundups) are driving attention but not a clear consensus; some authors highlight valuation appeal while noting macro and currency risks. GEHC or ABT: Which Is the Better Value Stock Right Now?
• Neutral Sentiment: Investor guides and sector lists name Abbott among steady healthcare picks for long‑term growth (dividend history, nutrition and Libre growth cited), supporting longer‑term investor interest even if near‑term volatility persists. Best Healthcare Stocks to Buy Right Now for Long-Term Growth
• Negative Sentiment: Analyst actions and comments are mixed: BTIG cut its price target (though maintained a Buy), signaling revised near‑term expectations; downward PT moves can pressure the stock. BTIG lowers price target on Abbott
• Negative Sentiment: Market concern about a recent soft quarter and a revenue miss (and the stock’s slide from its 52‑week high) is keeping selling pressure; near‑term headwinds include currency and macro uncertainty. This Dividend King Is Down 26%. When Will It Bounce Back?
• Negative Sentiment: Short‑term price action: coverage noting recent daily dips and lower trading volume versus average suggests current momentum is weak despite the strategic positives. Abbott (ABT) Dips More Than Broader Market: What You Should Know

Abbott Laboratories Trading Down 0.3%

Shares of NYSE:ABT opened at $102.41 on Thursday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58. The stock’s 50-day moving average is $109.68 and its 200-day moving average is $121.44. The company has a market cap of $178.36 billion, a P/E ratio of 27.53, a P/E/G ratio of 1.64 and a beta of 0.79. Abbott Laboratories has a 52-week low of $100.88 and a 52-week high of $139.06.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. During the same quarter in the previous year, the firm earned $1.34 EPS. The firm’s revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio is currently 67.74%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.